Daa Pangenotypic Epclusa denied for missing prior authorization by Humana?

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Epclusa

Epclusa (sofosbuvir/velpatasvir) is subject to prior authorization (PA) under most Humana commercial and Medicare Part D plans. This is a standard utilization-management tool, not a final clinical judgment. Humana's PA requirement exists because hepatitis C treatment involves confirming genotype, cirrhosis status, prior treatment history, and prescriber specialty — information that must be actively submitted rather than assumed. A PA denial typically means the required information was incomplete or did not clearly satisfy Humana's published clinical criteria at the time of review.

PA denials are fully appealable, and approval rates improve substantially when the appeal includes a complete, well-organized clinical submission addressing each criterion in Humana's hepatitis C coverage policy.

## Federal Appeal Framework

• ACA Section 2719 / external review: If your plan is non-grandfathered, you may request independent external review by an accredited IRO after exhausting internal appeals. The standard window is approximately four months from the denial notice; check your Explanation of Benefits for the exact deadline. Expedited external review (roughly 72 hours) is available when your situation is urgent.
• ERISA Section 503: Employer-sponsored plans must offer a full-and-fair review, written reasons for denial, and access to the criteria applied.
• Urgent / concurrent review: If treatment is already underway or delay poses a clinical risk, request expedited PA reconsideration and note the urgency explicitly.

## Concrete Appeal Steps and Timeline

1. Obtain the PA denial letter and identify exactly which criteria Humana determined were not met. 2. Download Humana's current hepatitis C or pangenotypic DAA PA criteria from their provider portal. 3. Submit a Level 1 internal appeal or a peer-to-peer review request (prescriber calls Humana's medical director directly — often the fastest path). 4. If upheld, file for external review within the deadline on the denial notice.

## Documentation to Gather

• Diagnosis confirmation: Hepatitis C genotype result, quantitative viral load, and fibrosis/cirrhosis staging via biopsy or elastography.
• Prior-treatment history: Names, dates, and outcomes of all prior hepatitis C regimens, including any DAA or interferon-based therapies.
• Prescriber specialty and attestation: Documentation that the prescribing provider is a gastroenterologist, hepatologist, or infectious disease specialist — or a primary care provider with appropriate hepatitis C management experience — as Humana's policy may specify.
• Clinical severity and comorbidities: Chart notes addressing hepatic function, HIV co-infection status, renal profile, and any other factors referenced in the Epclusa prescribing label or Humana's criteria.
• Medical-necessity letter: A detailed prescriber letter mapping the patient's clinical findings to each PA criterion.

## Criteria-Mapping Structure

From (a) the FDA-approved Epclusa prescribing information and (b) Humana's published PA criteria for hepatitis C, list every requirement and answer each one with a specific chart citation. Submit this as an exhibit to the appeal letter. Peer-to-peer review, requested by the prescriber, often resolves PA denials faster than a written appeal alone.